Neuropace Inc (NASDAQ:NPCE) — Market Cap & Net Worth
Market Cap & Net Worth: Neuropace Inc (NPCE)
Neuropace Inc (NASDAQ:NPCE) has a market capitalization of $516.86 Million ($516.86 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12234 globally and #3001 in its home market, demonstrating a -5.01% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuropace Inc's stock price $15.16 by its total outstanding shares 34093745 (34.09 Million). Review Neuropace Inc debt and liabilities to assess the company's total debt and financial obligations.
Neuropace Inc Market Cap History: 2021 to 2026
Neuropace Inc's market capitalization history from 2021 to 2026. Data shows change from $343.66 Million to $516.86 Million (-9.22% CAGR).
Index Memberships
Neuropace Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.02% | #325 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1188 of 3165 |
Weight: Neuropace Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neuropace Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neuropace Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.26x
Neuropace Inc's market cap is 5.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $343.66 Million | $45.18 Million | -$36.08 Million | 7.61x | N/A |
| 2022 | $50.80 Million | $45.52 Million | -$47.08 Million | 1.12x | N/A |
| 2023 | $351.51 Million | $65.42 Million | -$32.96 Million | 5.37x | N/A |
| 2024 | $381.51 Million | $79.91 Million | -$27.14 Million | 4.77x | N/A |
| 2025 | $526.41 Million | $99.99 Million | -$21.46 Million | 5.26x | N/A |
Competitor Companies of NPCE by Market Capitalization
Companies near Neuropace Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Neuropace Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #149 globally with a market cap of $153.89 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #212 globally with a market cap of $115.24 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #236 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #252 globally with a market cap of $100.32 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #149 | Abbott Laboratories | NYSE:ABT | $153.89 Billion | $88.50 |
| #212 | Stryker Corporation | NYSE:SYK | $115.24 Billion | $301.14 |
| #236 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #252 | Medtronic PLC | NYSE:MDT | $100.32 Billion | $78.14 |
Neuropace Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Neuropace Inc's market cap moved from $343.66 Million to $ 516.86 Million, with a yearly change of -9.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $516.86 Million | -1.81% |
| 2025 | $526.41 Million | +37.98% |
| 2024 | $381.51 Million | +8.54% |
| 2023 | $351.51 Million | +591.95% |
| 2022 | $50.80 Million | -85.22% |
| 2021 | $343.66 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Neuropace Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $516.86 Million USD |
| MoneyControl | $516.86 Million USD |
| MarketWatch | $516.86 Million USD |
| marketcap.company | $516.86 Million USD |
| Reuters | $516.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more